Loratadine
FDA-approved product (tablet, oral), marketed as Alavert, Children's Claritin, Claritin and 5 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Allergic disease
- Allergic rhinitis
- Pruritus
- Rhinitis, Allergic, Perennial
- Seasonal allergic rhinitis
- Urticaria
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antihistamines for systemic use
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli35.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae18.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Loratadine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria
NCT00525382 · start 2003-08
Registered record
- Registry ID
- NCT00525382
- Conditions
- Urticaria
- Interventions
- levocetirizine dihydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-08
- Completion
- 2004-03
- Enrolment
- 134
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUrticariaInterventionlevocetirizine dihydrochloridePhasePhase 3Registry statusCompletedMontelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)
NCT00963469 · start 2001-08
Registered record
- Registry ID
- NCT00963469
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- montelukast sodium; Comparator: loratadine; Comparator: placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-08
- Completion
- 2001-11
- Enrolment
- 1,079
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeasonal Allergic RhinitisInterventionmontelukast sodium; Comparator: loratadine; Comparator: placeboPhasePhase 3Registry statusCompletedRandomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)
NCT02932774 · start 2001-03
Registered record
- Registry ID
- NCT02932774
- Conditions
- Allergic Rhinitis; Hay Fever; SAR; Rhinitis, Allergic, Seasonal
- Interventions
- Cetirizine; Loratadine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2001-03
- Completion
- 2001-07
- Enrolment
- 683
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAllergic Rhinitis; Hay Fever; SAR; Rhinitis, Allergic, SeasonalInterventionCetirizine; Loratadine; PlaceboPhasePhase 4Registry statusCompletedA Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)
NCT00960141 · start 2000-08
Registered record
- Registry ID
- NCT00960141
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- montelukast sodium; Comparator: loratadine; Comparator: placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2000-08
- Completion
- 2000-11
- Enrolment
- 829
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeasonal Allergic RhinitisInterventionmontelukast sodium; Comparator: loratadine; Comparator: placeboPhasePhase 3Registry statusCompletedSafety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)
NCT03855228 · start 1995-03-01
Registered record
- Registry ID
- NCT03855228
- Conditions
- Rhinitis, Allergic
- Interventions
- Mometasone furoate nasal spray (MFNS); Loratadine; Placebo nasal spray; Placebo tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1995-03-01
- Completion
- 1995-08-07
- Enrolment
- 704
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRhinitis, AllergicInterventionMometasone furoate nasal spray (MFNS); Loratadine; Placebo nasal spray; Placebo tabletPhasePhase 3Registry statusCompleted